We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline have announced the results of a three year investigation into a long acting, injectable, two-drug HIV regimen at the HIV Glasgow Drug Therapy meeting in Scotland.